Keyphrases
Tumor Vasculature
100%
Endothelial Monocyte-activating polypeptide-II
100%
Tumor Necrosis Factor-α
66%
Endothelial Cells
50%
PSMA7
41%
Hypoxia-inducible factor-1α (HIF-1α)
41%
Antivascular Therapy
25%
Tumor-host Interactions
25%
Pancreas
25%
Virus
25%
Tumor
25%
Vascular Treatment
25%
Tumor Growth
16%
Mouse Model
16%
Transgenic Mouse Model
16%
Tumor Angiogenesis
16%
Angiogenesis
16%
Antiangiogenic Activity
16%
Antiangiogenic
16%
TC-1
16%
KLF4
16%
Quantification Method
16%
Spontaneous Tumors
16%
Pancreatic Neuroendocrine Tumors (pNETs)
16%
Tumor Formation
16%
Neuroendocrine Tumor
16%
Virus-like Particles
16%
Multiple Endocrine Neoplasia Type 1 (MEN1)
16%
Transgenic
8%
26S Proteasome
8%
Binding Site
8%
Binding Partners
8%
Image-guided
8%
Antiangiogenic Agents
8%
Molecular Mechanism
8%
Apoptosis
8%
Mechanism of Action
8%
Inhibitory Effect
8%
Transcriptional Activity
8%
Mouse Xenograft
8%
Gene Regulation
8%
Mammalian Cells
8%
Inflammatory Cytokines
8%
Tumor Progression
8%
Genetic Mechanism
8%
Tumor-associated Vasculature
8%
Tumor Development
8%
Comparative Oncology
8%
Clinical Setting
8%
Single Administration
8%
Endothelial Tube Formation
8%
RECIST Criteria
8%
Multiplex Real-time PCR
8%
Cre-lox System
8%
Vascular Structure
8%
Pathway-targeted Therapy
8%
Successful Development
8%
Proteasome Complex
8%
Targeted Tumor
8%
Targeted Delivery
8%
Von Hippel-Lindau Disease
8%
Tumor Vasculature Targeting
8%
Vascular Tumor
8%
Human Melanoma
8%
Response Evaluation Criteria in Solid Tumors (RECIST)
8%
Mimicking Tumor
8%
Xenograft Tumor Model
8%
Tropism
8%
Tumor Bed
8%
Vessel Analysis
8%
Tumor Mimics
8%
Prostate Cancer
8%
Human Cancer
8%
Tumor Suppressor
8%
Vessel Quantification
8%
Companion Dogs
8%
Integrin Ligands
8%
4-cycle
8%
Selective Deletion
8%
Phase I Clinical Trial
8%
Tumor Suppressor Gene
8%
Large Animal Model
8%
Targeted Therapy
8%
Systemic Delivery
8%
Clinically Significant
8%
Vasculature
8%
Integrin Receptor
8%
Upstream Regulator
8%
Laboratory Investigation
8%
Gene Products
8%
Human Endothelial Cells
8%
Systemic Administration
8%
Human Tissue
8%
Cytokine Regulation
8%
Metastatic Tumor
8%
Tumor Reduction
8%
Image Quantification
8%
Tumor Stage
8%
β3-integrin
8%
Surrogate Method
8%
Bacteriophage
8%
Angiogenesis Inhibitors
8%
Von Hippel-Lindau Syndrome
8%
Small Interfering RNA (siRNA)
8%
Tumorigenesis
8%
Current Vector
8%
Muscularis
8%
Primary Tumor
8%
CDNA Microarray Analysis
8%
Vector System
8%
Repeated Administration
8%
Medicine and Dentistry
Tumor Vascularization
66%
Endothelial Monocyte Activating Polypeptide II
66%
Malignant Neoplasm
66%
Tumor Necrosis Factor
61%
Neoplasm
61%
Endothelial Cell
44%
Hypoxia Inducible Factor 1
27%
Targeted Therapy
22%
Cytokine
16%
Tumor Progression
16%
Carcinogenesis
16%
Virus
16%
Angiogenesis
11%
Angiogenesis Inhibitor
11%
Pancreas Islet Cell Tumor
11%
Vascular Tissue Neoplasm
11%
Multiple Endocrine Neoplasia Type I
11%
Transgenic Mouse
11%
Tumor Angiogenesis
11%
Vascularity
11%
Antiangiogenic Activity
11%
Antiangiogenic
11%
Neuroendocrine Tumor
11%
Kruppel Like Factor 4
11%
Virus Particle
11%
Human Tissue
5%
Downregulation
5%
Prostate Cancer
5%
Tumor Model
5%
Stroma
5%
Reverse Transcription Polymerase Chain Reaction
5%
Tumor Suppressor Gene
5%
In Vitro
5%
Repeated Drug Dose
5%
Blood Vessel
5%
Single Drug Dose
5%
cDNA Microarray
5%
Beta3 Integrin
5%
Metastatic Carcinoma
5%
Protein
5%
Programmed Cell Death
5%
Microarray Analysis
5%
Oncology
5%
Mammalian Cell
5%
Proteasome
5%
Von Hippel-Lindau Disease
5%
Vascular Agent
5%
Very Late Activation Antigen 5
5%
Systemic Administration
5%
Primary Tumor
5%
Gene Control
5%
Gene Therapy
5%
Binding Site
5%
Gene Product
5%
Clinical Trial
5%
Integrin Receptor
5%
Xenograft
5%
Tumor Suppressor Protein
5%
Melanoma
5%
Bacteriophage
5%
Biochemistry, Genetics and Molecular Biology
Tumor Vascularization
100%
Tumor Necrosis Factor
100%
Tumor Necrosis Factor Alpha
72%
Angiogenesis
45%
Hypoxia Inducible Factor 1
45%
Mouse Model
36%
Tumor Progression
27%
Carcinogenesis
27%
Transgenic Mouse
18%
Antiangiogenic Activity
18%
Cytokine
18%
KLF4
18%
Virus Particle
18%
Vascularization
18%
Integrin
18%
Reverse Transcription Polymerase Chain Reaction
9%
Tumor Suppressor Protein
9%
Genetic Mechanism
9%
Gene Control
9%
Proinflammatory Cytokine
9%
Transgenics
9%
Proteasome
9%
Downregulation
9%
Animal Model
9%
Clinical Trial
9%
TaqMan
9%
cDNA Microarray
9%
Repeated Drug Dose
9%
Single Drug Dose
9%
Von Hippel-Lindau Disease
9%
Binding Site
9%
Gene Product
9%
Tumor Suppressor Gene
9%
Gene Therapy
9%
Bacteriophage
9%
Programmed Cell Death
9%